Sirolimus for visceral and cutaneous Kaposi's sarcoma in a renal-transplant recipient

被引：4

作者：

Gheith O. ^{[1
]}

Bakr A. ^{[1
]}

Wafa E. ^{[1
]}

Fouda A. ^{[1
]}

El Agroudy A. ^{[1
]}

Refaie A. ^{[1
]}

Donia A. ^{[1
]}

Sabry A. ^{[1
]}

Sobh M. ^{[1
]}

Shokeir A. ^{[1
]}

Ghoneim M. ^{[1
]}

机构：

[1] Urology and Nephrology Center, Mansoura University, Mansoura, Gomhoria St.

来源：

Clinical and Experimental Nephrology | 2007年 / 11卷 / 3期

关键词：

Malignancy; Renal transplant; Sirolimus;

D O I：

10.1007/s10157-007-0470-y

中图分类号：

学科分类号：

摘要：

The incidence of Kaposi's sarcoma among recipients of solid organs is about 500 times the rate in the general population, suggesting a role for immunosuppression in its development. On the basis of these findings, we investigated the impact of sirolimus on cutaneous and disseminated visceral Kaposi's sarcoma in a renal-transplant recipient. The introduction of sirolimus in this patient allowed complete regression of Kaposi's sarcoma (cutaneous and visceral) with preservation of excellent renal function. Meanwhile, in view of the available observational reports, we think that sirolimus should be included in the standard treatment for Kaposi's sarcoma after transplantation, to permit remission of the sarcoma (both cutaneous and visceral) while preserving the renal function. © 2007 Japanese Society of Nephrology.

引用

页码：251 / 254

页数：3

共 16 条

[1]

Hayward G.S., Initiation of angiogenic Kaposi's sarcoma lesions, Cancer Cell, 3, pp. 1-3, (2003)

[2]

Penn I., Cancers in cyclosporine-treated vs azathioprine-treated patients, Transplant Proc, 28, pp. 876-8, (1996)

[3]

Doutrelepont J.M., De Pauw L., Gruber S.A., Dunn D.L., Qunibi W., Kinnaert P., Et al., Renal transplantation exposes patients with previous Kaposi's sarcoma to a high risk of recurrence, Transplantation, 62, pp. 463-6, (1996)

[4]

Chang Y., Cesarman E., Pessin M.S., Lee F., Culpepper J., Knowles D.M., Et al., Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma, Science, 266, pp. 1865-9, (1994)

[5]

Marchio S., Primo L., Pagano M., Palestro G., Albini A., Veikkola T., Et al., Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells, J Biol Chem, 274, 27, pp. 617-722, (1999)

[6]

Guba M., Graeb C., Jauch K.W., Geissler E.K., Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation, Transplantation, 77, pp. 1777-82, (2004)

[7]

Luan F.L., Ding R., Sharma V.K., Chon W.J., Lagman M., Suthanthiran M., Rapamycin is an effective inhibitor of human renal cancer metastasis, Kidney Int, 63, pp. 917-26, (2003)

[8]

Morath C., Mueller M., Goldschmidt H., Schwenger V., Opelz G., Zeier M., Malignancy in renal transplantation, J Am Soc Nephrol, 15, pp. 1582-8, (2004)

[9]

Moosa M.R., Racial and ethnic variations in incidence and pattern of malignancies after kidney transplantation, Medicine (Baltimore), 84, pp. 12-22, (2005)

[10]

Luppi M., Barozzi P., Rasini V., Riva G., Re A., Rossi G., Et al., Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet, Transplantation, 74, pp. 131-2, (2002)

← 1 2 →